Also known as: Tezspire, TEZSPIRE
Recent research identifies hidden systemic inflammation in primary ciliary dyskinesia via oral swab and confirms asthma biologics do not increase respiratory infection risk in pediatric patients.
A placebo-controlled trial shows tezepelumab significantly reduces oral corticosteroid dependence in severe asthma, with patients achieving nearly three times the odds of reduction versus placebo. A separate case report documents dramatic functional recovery in an elderly patient who switched from mepolizumab to tezepelumab after inadequate response.
Aclaris Therapeutics outlined its TSLP antibody and ITK kinase pipeline at the Guggenheim Biotech Summit, with Phase II AD results for bosakitug due in late 2026 and Phase 1b studies for bispecific ATI-052 underway. The company will also announce Phase 1a results for ATI-052 and lead indication selection for ATI-2138 on April 28, 2026.
Barclays initiated Amgen with an Equal Weight rating and a $185 price target as debate over the Phase 3 MARITIME trial continued. Amgen said 2025 revenue and earnings per share rose by double digits.
Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.
